Moneycontrol PRO
Upcoming Event:Join us for New HorAIzon from Oct 6-7, 2pm and be a part of exciting conversations on tech & innovation

Buy Glenmark Pharmaceuticals; target of Rs 840: Axis Direct

Axis Direct is bullish on Glenmark has recommended buy rating on the stock with a target price of Rs 840 in its research report dated August 02, 2017.

August 07, 2017 / 03:11 PM IST
Aurobindo Pharma Ltd.

Aurobindo Pharma Ltd.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Axis Direct's report on Glenmark Pharmaceuticals


Q1FY18 PAT at Rs 3.33 bn (+47% YoY) beat consensus estimate on strong growth in the US (55% YoY) and India business (15% YoY). gZetia sales was USD 55 mn (achieving guidance of USD 170-180 mn during exclusivity) and helped reduce net debt by Rs 3 bn. Company expects higher R&D (13% of sales) in Q2 given Ph-2 trials for GBR 830 and Ph-3 trials for GSP 304, only to normalize to 11% in FY18. It expects US base business growth to improve (more so in H2) on 3-4 derma products. It expects 8-10% sales growth with 22% margin in FY18 (in line with our expectations).


Outlook


We maintain BUY and FY18/19E estimates. Raise TP to Rs 840 (18x FY19E EPS; vs. 800 earlier at 17x) given debt reduction, its strong R&D pipeline in US, steady India and improving EM business. NCE licensing income critical to further improve B/S and C/F in our view.


For all recommendations report, click here


Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

first published: Aug 7, 2017 03:11 pm

stay updated

Get Daily News on your Browser
Sections
ISO 27001 - BSI Assurance Mark